Search results | royalty financing

Reports

Royalty Financing Terms and Agreements

The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

Insights

Royalty financing

A sale of rights to royalties for sale of the product which would have otherwise been due to the licensor…

The growth of synthetic royalty financing

A recent study (report: Royalty Financing Terms and Agreements) has shown a significant increase in the use of royalty and revenues based financing as an alternative way for biotechs to raise finance

Industry trend analysis: royalty and revenue financing deals

This article talks about the industry trend analysis of signing royalty and revenue financing deals among life science sectors

Synthetic royalty

A royalty created where none had previously existed. The royalty stream is generated from future sales …

Revenue financing

A royalty created where none had previously existed. The royalty stream is generated from future…

PDL Biopharma : Partnering and Financing activity 2009-2014

PDL Biopharma, formerly known as Protein Design labs, is headquartered in Nevada.

Elan receives $6.7 billion M&A offer from Royalty Pharma with options to the overall sum of $8 billion

Royalty Pharma has raised its bid for Elan again. With sum m&a value now sitting at $6.7 billion with options bringing the overall deal value to $8 billion.

Elan rejects Royalty Pharma acquisition offer

Offer for $11.25 or less per share, substantially undervalues the company according to Elan execs

Royalty Pharma makes acquisition offer to Elan shareholders

Royalty Pharma announces firm acquisition offer to acquire Elan, with a $12 a share proposal

Alitair offers ion exchange resin patents and royalty stream in sealed bid sale

Alitair Pharmaceuticals has retained Finn, Warnke & Gayton, to sell two Alitair patents and an associated royalty stream at a sealed bid sale on May 24, 2013

Events

Sorry, your search returned no results.


Deals

Immunogen gains $200 million from Kadcyla royalty financing

ImmunoGen announced a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners

Vertex in $3.3 billion royalty financing with Royalty Pharma

Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics

Rush University Medical Center receives $42 million in royalty financing

DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.

Supernus pharma raises $30 million by royalty financing

Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners.

Ophthotech received its second royalty financing for $41.7 million

Ophthotech has received payment of approximately $41.7 million in a second tranche in royalty financing from Novo.

Royalty Pharma receives $510 million in royalty financing

Royalty Pharma has acquired an additional interest in the royalty financing to the former shareholders of Fumapharm AG for $510 million in cash.

Royalty Pharma sells $485 million interest to Aisling Capital and Clarus Ventures in royalty financing round

Royalty Pharma has sold it’s $485 million interest in Ibrutinib to Aisling Capital and Clarus Ventures in a royalty financing round.

Elan & Theravance enter $1 billion royalty financing deal

Elan has completed life science deals with Theravance for royalties of previous GlaxoSmithKline deals in a $1 billion royalty financing deal.

Capital Royalty announces $805m in royalty financing

Capital Royalty announced the final closing of Capital Royalty Partners II with $805 million in equity financing.

Vivus in royalty financing for $110 million

VIVUS has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors.